Company: TXG
Filing Date: 2025-11-07
Form Type: 10-Q
Source: 0001628280-25-050332
Chunk: 47

Company: 10x Genomics, Inc.
Filing Date: 2025-11-07
Form: 10-Q
Item: Part I, Item 8
Chunk 47
---
Expense), NetGains or losses from foreign currency remeasurement are included in “Other income (expense), net” in the condensed consolidated statements of operations. The Company recognized foreign currency transaction loss of $0.6 million for the three months ended September 30, 2025, and foreign currency transaction income of $3.1 million for the nine months ended September 30, 2025. The Company recognized foreign currency transaction income of $1.3 million and $0.3 million for the three and nine months ended September 30, 2024, respectively.The change in fair value of contingent consideration are included in “Other income (expense), net” in the condensed consolidated statements of operations. The company recognized the $1.1 million loss due to change in fair value of contingent consideration for the three and nine months ended September 30, 2025.

6.    Commitments and Contingencies

Lease AgreementsThe Company leases office, laboratory, manufacturing, distribution and server space in various locations worldwide. As of September 30, 2025, the Company recorded $1.8 million in right of use asset and lease liabilities in connection with Scale acquisition. See Note 3, Asset Acquisition, for details related to right of use assets and lease liabilities acquired.The payments due under the Company’s operating lease liabilities as of September 30, 2025 are as follows (in thousands):Operating Leases2025 (excluding the nine months ended September 30, 2025)$2,971 202616,612 202716,799 202816,382 202914,788 Thereafter39,314 Total lease payments$106,866 Less: imputed interest(19,881)Present value of operating lease liabilities$86,985 Operating lease liabilities, current$10,543 Operating lease liabilities, noncurrent76,442 Total operating lease liabilities$86,985 The following table summarizes additional information related to operating leases as of September 30, 2025:September 30,2025December 31,2024Weighted-average remaining lease term6.9 years6.8 yearsWeighted-average discount rate5.9 %5.8 %

15

Table of Contents10x Genomics, Inc.Notes to Unaudited Condensed Consolidated Financial Statements

LitigationThe Company is regularly subject to lawsuits, claims, arbitration proceedings, administrative actions and other legal and regulatory proceedings involving intellectual property disputes,